Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures a meta-analysis

被引:32
作者
Hammond, Rebecca [2 ]
Harry, Tubonye C. [1 ]
机构
[1] James Paget Univ Hosp NHS Trust, Bure Clin, Great Yarmouth NR31 6LA, Norfolk, England
[2] Norfolk & Norwich Univ Hosp NHS Trust, Norwich NR4 7UY, Norfolk, England
关键词
meta-analysis; antiretroviral drugs; sub-Saharan Africa; viral load; CD4; count;
D O I
10.1258/ijsa.2007.007248
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study is a systematic literature review exploring the efficacy of antiretroviral therapy (ART) in Africa through a meta-analysis of immunological and virological outcome measures at baseline and six subsequent time points. A literature search was conducted through two databases and references of relevant papers searched. The inclusion criteria were papers with data from the African continent with predominantly an adult population, who were ART naive and human immunodefieciency virus-1-positive, data on the CD4 count and/or percentage undetectable viral load (UDVL) at a subsequent time-point following ART initiation. The search identified 368 papers. Of these 320 were excluded by title and abstract, 48 papers were accessed with a further 19 papers then excluded. Twenty-nine papers from 12 countries were included in the meta-analysis. All papers showed evidences of Grade III or IV. The mean CD4 count (cells/mm(3)) at baseline was 141.0 and viral load was 5.2 log(10). The mean CD4 count was 243.8, 248.9, 277.1, 274.1, 298.4, 374 at 3, 6,12,18, 24 and > 24 months, respectively. The mean percentage with UDVL was 73.3, 74.7, 66.9, 68.1, 64.6, 73.5 at 3, 6,12,18, 24 and > 24 months, respectively. In conclusion, the meta-analysis provides evidence that ART increases the CD4 count from three months until three years, and the majority of subjects had an UDVL (< 400 copies/mL) at each analysed time-point. Though the grade of evidence is low, this analysis suggests that ART can be provided successfully within the continent of Africa even with the limitations of a resource-poor setting.
引用
收藏
页码:291 / 296
页数:6
相关论文
共 38 条
[1]   Diagnostic virologic accuracy of CD4 cell count increase for response after initiating highly active antiretroviral therapy [J].
Bisson, Gregory P. ;
Gross, Robert ;
Strom, Jordan B. ;
Rollins, Caitlin ;
Bellamy, Scarlett ;
Weinstein, Rachel ;
Friedmand, Harvey ;
Dickinson, Diana ;
Frank, Ian ;
Strom, Brian L. ;
Gaolathe, Tendani ;
Ndwapi, Ndwapi .
AIDS, 2006, 20 (12) :1613-1619
[2]  
Bourgeois A, 2005, ANTIVIR THER, V10, P335
[3]   Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa [J].
Coetzee, D ;
Boulle, A ;
Hildebrand, K ;
Asselman, V ;
Van Cutsem, G ;
Goemaere, E .
AIDS, 2004, 18 :S27-S31
[4]   Tolerance and acceptability of an efavirenz-based regimen in 740 adults (Predominantly women) in West Africa [J].
Danel, C ;
Moh, R ;
Anzian, A ;
Abo, Y ;
Chenal, H ;
Guehi, C ;
Gabillard, D ;
Sorho, S ;
Rouet, F ;
Eholié, S ;
Anglaret, X .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (01) :29-35
[5]   Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire [J].
Djomand, G ;
Roels, T ;
Ellerbrock, T ;
Hanson, D ;
Diomande, F ;
Monga, B ;
Maurice, C ;
Nkengasong, J ;
Konan-Koko, R ;
Kadio, A ;
Wiktor, S ;
Lackritz, E ;
Saba, J ;
Chorba, T .
AIDS, 2003, 17 :S5-S15
[6]   PUBLICATION BIAS IN CLINICAL RESEARCH [J].
EASTERBROOK, PJ ;
BERLIN, JA ;
GOPALAN, R ;
MATTHEWS, DR .
LANCET, 1991, 337 (8746) :867-872
[7]   Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment [J].
Ferradini, L ;
Jeannin, A ;
Pinoges, L ;
Izopet, J ;
Odhiambo, D ;
Mankhambo, L ;
Karungi, G ;
Szumilin, E ;
Balandine, S ;
Fedida, G ;
Carrieri, MP ;
Spire, B ;
Ford, N ;
Tassie, JM ;
Guerin, PI ;
Brasher, C .
LANCET, 2006, 367 (9519) :1335-1342
[8]   Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: Normal clinical practice versus clinical trial findings [J].
Fethi, T ;
Asma, J ;
Amine, SM ;
Amel, EGA ;
Taoufik, BC ;
Mohamed, C ;
Amel, LO ;
Mounira, G .
CURRENT HIV RESEARCH, 2005, 3 (03) :271-276
[9]   Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real-life situation in 2002 [J].
Fischer, A ;
Karasi, JC ;
Kibibi, D ;
Omes, C ;
Lambert, C ;
Uwayitu, A ;
Hemmer, R ;
Van Den Ende, J ;
Schmit, JC ;
Arendt, V .
HIV MEDICINE, 2006, 7 (01) :64-66
[10]   Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy [J].
Frater, AJ ;
Dunn, DT ;
Beardall, AJ ;
Ariyoshi, K ;
Clarke, JR ;
McClure, MO ;
Weber, JN .
AIDS, 2002, 16 (08) :1139-1146